Protara Therapeutics (TARA) Operating Expenses (2013 - 2026)

Protara Therapeutics' Operating Expenses history runs 14 years deep, the most recent figure standing at $19.6 million for Q1 2026.

• In Q1 2026, Operating Expenses rose 38.98% year-over-year to $19.6 million; the TTM figure through Mar 2026 stood at $70.1 million (up 36.22% YoY), while the FY2025 annual figure was $64.5 million, up 31.32% from the prior year.
• Operating Expenses was $19.6 million for Q1 2026 at Protara Therapeutics, up from $19.1 million in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $39.5 million in Q4 2022 to a low of $8.0 million in Q3 2022.
• Historically, Operating Expenses has averaged $14.4 million across 5 years, with a median of $12.1 million in 2023.
• The sharpest annual moves came in 2022 and 2023: Operating Expenses surged 284.07% in 2022, then slumped 72.05% in 2023.
• A 5-year view of Operating Expenses shows it stood at $39.5 million in 2022, then plunged by 72.05% to $11.0 million in 2023, then grew by 29.63% to $14.3 million in 2024, then jumped by 33.31% to $19.1 million in 2025, then rose by 2.88% to $19.6 million in 2026.
• The last three Operating Expenses figures came in at $19.6 million (Q1 2026), $19.1 million (Q4 2025), and $14.8 million (Q3 2025), per Business Quant data.